Werewolf Therapeutics stock gains on merger scrutiny and trial progress

Werewolf Therapeutics stock (ISIN US4433141076) is trading around the 1.00 dollar mark on Nasdaq as of September 3, 2026, after closing at 1.00 dollars with a 4.26 percent gain according to market data compiled by MarketBeat.

Merger investigations add pressure

Recent headlines show that shareholder rights law firms have launched investigations into whether the planned merger of Werewolf Therapeutics offers a fair price to existing investors, adding legal scrutiny to the stock's story.

According to the MarketBeat stock overview for Werewolf Therapeutics as of September 3, 2026, recent news flow includes alerts from shareholder law firms questioning whether the valuation in the merger agreement adequately reflects the companys prospects.

Analyst view and upside potential

The same MarketBeat data shows that analysts currently assign Werewolf Therapeutics an average rating score of 2.14 on a scale where lower scores indicate more cautious views, based on 2 buy, 4 hold and 1 sell ratings as of early September 2026.

Consensus figures compiled in the MarketBeat overview indicate a price target of 4.00 dollars for Werewolf Therapeutics stock, implying upside potential of about 312.4 percent from a reference price of 0.97 dollars as stated in the September 2, 2026 snapshot.

Cancer trial progress supports the story

Beyond the merger debate, the companys pipeline is central to the investment thesis. Recent coverage summarised in the MarketBeat news section highlights that Werewolf Therapeutics has completed a key early trial for its candidate WTX-124 in hard-to-treat cancers, with the headline dated August 27, 2026.

Another item reported in late August 2026 points to Werewolf Therapeutics securing a 150 million dollar funding boost, a figure that stands out for retail investors because it represents a multiple of the companys market value at a sub-1.00 dollar share price level.

Representative product and pipeline focus

WTX-124, mentioned in the August 27, 2026 news coverage, is an important representative asset in Werewolf Therapeutics pipeline because it is being tested in patients with hard-to-treat cancers and has recently moved through a key early-stage clinical milestone.

Stock level and investor perspective

As of the close on September 3, 2026, Werewolf Therapeutics stock trades at 1.00 dollars on Nasdaq, while the MarketBeat performance overview notes that from a previous reference point the shares have risen by 53.1 percent to reach 0.97 dollars, underlining both recent strength and the volatility associated with penny stocks.